All articles tagged with #chromogranin a
UCSD researchers identify chromogranin A (CgA) as a key driver linking amyloid-beta/tau pathology to cognitive decline: mice lacking CgA still develop Alzheimer’s brain changes but remain cognitively sharp, revealing innate resilience mechanisms and a potential preventive target, though human confirmation and safety considerations are needed, and some authors have industry ties.
UCSD researchers used an AI-driven approach to identify chromogranin A as a molecular switch deciding whether Alzheimer’s pathology translates into memory loss. In tauopathy mice, removing CgA preserved learning and memory despite brain pathology, with females showing stronger protection. They also found catestatin, a peptide derived from CgA, which lowered disease markers and protected cognition across several mouse models. All findings are preclinical and require replication, dosing, safety studies, and regulatory review before any human testing, but the work aims to shift Alzheimer’s research toward prevention-based strategies.
UC San Diego researchers have identified Chromogranin A as a potential molecular switch that could prevent Alzheimer’s-like memory loss; in mice, removing CgA protected against dementia, and peptides that interact with CgA may either provoke or prevent cognitive decline. An AI framework helped confirm consistent patterns across datasets and pinpoint peptides that could halt disease progression, suggesting a preventive, not curative, approach. While results are promising and described as safe in mice, human testing and further funding are needed.
Researchers report a 40-gene pattern that distinguishes normal aging, symptomatic Alzheimer's, and a resilient state, and identify Chromogranin A (CgA) as a stress-related protein that links cellular stress to Tau tangles. In mice, removing CgA reduced Tau buildup and preserved memory, especially in females, suggesting resilience pathways can sustain cognition despite brain damage. While promising, these findings are in animals and must be validated in humans, with resilience markers potentially guiding early prevention.